Andrew has more than 25 years of experience in finance and corporate development. Prior to joining Vaxcyte, Andrew served as Chief Financial Officer of Dermira, Inc. from April 2014 through the acquisition of the company by Eli Lilly and Company in February 2020. During his time at Dermira, Mr. Guggenhime executed on a wide range of financial and strategic transactions, including the company’s initial public offering, follow-on offerings and the sale of the company; planned and executed the transition to a commercial-stage organization in connection the company’s first product launch; and built and led business planning and process initiatives for multiple corporate functions. Prior to Dermira, Andrew served as Chief Financial Officer for CardioDx, Inc., a privately held commercial-stage molecular diagnostics life sciences company. He also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., a privately held, development-stage company, which was acquired by Gilead Sciences, Inc. in 2011; and as Chief Financial Officer for Facet Biotech Corporation, a biotechnology company that was acquired by Abbott Laboratories in April 2010. He previously served as Chief Financial Officer of PDL BioPharma, Inc. until Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, Mr. Guggenhime served as Chief Financial Officer for Neoforma, Inc. a provider of supply chain management solutions for the healthcare industry, which was acquired by Global Healthcare Exchange, LLC in March 2006. Mr. Guggenhime began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He currently serves on the board of directors of Metacrine, Inc., a privately held biotechnology company. Mr. Guggenhime holds an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in international politics and economics from Middlebury College. Andrew enjoys spending quality family time and traveling with his wife and three children, skiing, tennis and golf and, as a native San Franciscan, watching his hometown Giants, 49ers and Warriors.
What is Andrew Guggenhime's net worth?
The estimated net worth of Andrew Guggenhime is at least $7.77 million as of October 18th, 2024. Mr. Guggenhime owns 90,383 shares of Vaxcyte stock worth more than $7,769,323 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Guggenhime may own. Additionally, Mr. Guggenhime receives a salary of $820,810.00 as CFO at Vaxcyte. Learn More about Andrew Guggenhime's net worth.
How old is Andrew Guggenhime?
Mr. Guggenhime is currently 56 years old. There are 6 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., Senior Vice President of Process Development & Manufacturing, who is 63 years old. Learn More on Andrew Guggenhime's age.
What is Andrew Guggenhime's salary?
As the CFO of Vaxcyte, Inc., Mr. Guggenhime earns $820,810.00 per year. The highest earning executive at Vaxcyte is Mr. Grant E. Pickering M.B.A., Co-Founder, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Andrew Guggenhime's salary.
How do I contact Andrew Guggenhime?
Has Andrew Guggenhime been buying or selling shares of Vaxcyte?
During the past quarter, Andrew Guggenhime has sold $4,846,380.00 in shares of Vaxcyte stock. Most recently, Andrew Guggenhime sold 42,000 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a transaction totalling $4,846,380.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company's stock, valued at $10,429,294.37. Learn More on Andrew Guggenhime's trading history.
Who are Vaxcyte's active insiders?
Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?
In the last year, insiders at the sold shares 47 times. They sold a total of 422,090 shares worth more than $33,411,600.21. The most recent insider tranaction occured on November, 7th when CEO Grant Pickering sold 2,366 shares worth more than $245,803.74. Insiders at Vaxcyte own 3.1% of the company.
Learn More about insider trades at Vaxcyte. Information on this page was last updated on 11/7/2024.
